Streetbeat News

Stock Prices

NXPI

NXP Semiconductors (NASDAQ:NXPI) has delivered an average annual return of 15.44% over the past 10 years, outperforming the market by 4.62%. A $100 investment in NXPI a decade ago would be worth $429.34 today. The company's current market capitalization stands at $62.10 billion.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 7:30 pm

AMPH

LLY

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) is exploring potential acquisitions in the endocrinology sector, leveraging its commercial infrastructure around Baqsimi, an inhaled glucagon product for severe hypoglycemia. At the Needham Healthcare Conference, the company expressed optimism about Baqsimi's market potential, citing its difficult-to-genericize nature and IP protection until 2036. Baqsimi, competing mainly with Gvoke, is expected to significantly increase its sales from $153 million in 2023 to a peak of $250-270 million. Despite a projected modest increase in product units sold and a slight decrease in prices in 2024 due to higher wholesaler fees paid by Eli Lilly And Co (NYSE:LLY), Amphastar anticipates new opportunities amid potential market re-entries by competitors. With $300 million in cash reserves and strong cash flow, Amphastar is considering debt financing for acquisitions. Needham maintains a Hold rating on AMPH, whose shares recently dropped 2.33% to $39.95.

Portfolio Pulse from Vandana Singh

April 10, 2024 | 7:24 pm

WYNN

Barclays analyst Brandt Montour has maintained an Overweight rating on Wynn Resorts (NASDAQ:WYNN) and increased the price target from $117 to $123.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 7:19 pm

WFC

Deep-pocketed investors show a divided sentiment on Wells Fargo (NYSE:WFC), with unusual options activity indicating both bullish and bearish positions. The activity focuses on a price band between $45.0 and $60.0. The stock is currently trading at $56.66, with an earnings announcement expected in 2 days. This mixed sentiment and upcoming earnings could lead to increased volatility in WFC's stock price.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 7:16 pm

ADBE

Financial analysis reveals a bearish trend in Adobe's (NASDAQ:ADBE) options market, with 59% of trades showing bearish sentiment. The analysis highlighted 32 unusual trades, with a focus on a price range between $165.0 and $740.0 for Adobe. The largest trades included both bullish and bearish sentiments, with significant activity in calls and puts. Adobe's current stock price is down by -1.38%, with an average analyst price target of $602.2. Analyst ratings vary, with price targets ranging from $511 to $660.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 7:16 pm

EWZ

PBR

A Reddit user, SunsetKittens, highlights Petrobras (NYSE:PBR) as a compelling investment, citing its undervaluation and strong financials despite potential risks under President Lula's green energy focus. The iShares MSCI Brazil ETF (NYSE:EWZ), which includes Petrobras as its second-largest holding, offers broader exposure to Brazil's equity market. The discussion reflects mixed opinions on Petrobras' future amidst government policy uncertainties.

Portfolio Pulse from Surbhi Jain

April 10, 2024 | 7:14 pm

DOGE-USD

Dogecoin (DOGE) experienced a significant price increase following the last Bitcoin Halving in May 2020, with a 7,185% surge since then. Despite initial declines post-Halving, Dogecoin's price jumped 40% from June to July 2020, and despite a slight dip afterwards, it reached an all-time high of $0.68 in May 2021. Dogecoin's market cap has grown from $300 million in January 2020 to its current $28 billion, making it the eighth-largest cryptocurrency. The article also highlights the role of social media in Dogecoin's popularity surge.

Portfolio Pulse from Khyathi Dalal

April 10, 2024 | 7:10 pm

CAVA

Cava Group's stock price increased following an upgrade from Hold to Buy by Argus Research.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 7:08 pm

JANX

Janux Therapeutics is reportedly considering a sale, leading to an increase in its stock price.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 7:07 pm

ALPN

NVS

Alpine Immune Sciences Inc (NASDAQ:ALPN) is exploring strategic options, including a potential sale, due to interest from buyers. The company's stock has risen over 400% in the past year, partly due to promising clinical data on povetacicept for autoimmune glomerulonephritis. Novartis AG (NASDAQ:NVS) acquired Chinook Therapeutics last year, highlighting the growing interest in kidney disease treatments.

Portfolio Pulse from Vandana Singh

April 10, 2024 | 7:07 pm